Therefore, in this study, the targets of our vaccine were selected MUC1 and PD-L1, two molecules highly expressed on many kinds of tumor cells, in order to activate a sufficient amount of MUC1 or PD-L1 specific T cells to kill tumor cells more widely and comprehensively. The gene discussed is MUC1; the disease is neoplasm.